




Global Map: https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html.

This week, there are over 335 million cases and there are 5,560,696 deaths around the world.




Last week:


Total cases: 62,538,796 (over 62 million)

As of yesterday:

Total cases: 66,715,937



The 7 day average number of cases in the US is cases 755,095 per day. That is down a little from about 761,535 cases per day last week.




Last week:


Total deaths since the beginning of the pandemic: 840,286

As of yesterday:

This week: 850,575




The 7 day average number of deaths in the US is 1,669 deaths per day which is similar to last week at 1,656.




As of yesterday, in Kansas, we had 660,599 cases and 7,290 deaths statewide. That's an increase of 58,740 cases and 149 deaths reported since last week.


There were 39,326 new cases and 128 new deaths reported between Monday 1/17/2022 and Wednesday 1/19/2022.



Looking at the CDC Community Transmission Map between Wed Jan 12 2022 - Tue Jan 18 2022 every county in KS was in red indicating high transmission.



If you look at the 7 day average number of cases based on symptom onset date, starting with January 8 to January 14, our 7 day rolling average is 4,810 cases per day. Last week we were at 3,456 cases per day.




If you look at the 7 day average number of deaths based on the date of death, starting with January 8 to January 14, our 7 day rolling average is 9 deaths per day. Similar to last week when we were at about 8 deaths per day.

	Active CO	VID-19 Clusters	
Clusters	Cases	Hospitalizations	Deaths
275	4,616	61	52
Clusters	All COV	ID-19 Clusters Hospitalizations	Deaths
Clusters	Cases	Hospitalizations	Deaths
3,310	52,162	2,383	2,453
2 162 outbreak-relate	ed cases/660,599 cases (	7 0%)	

## Moving on to outbreaks:

As of late Tuesday night, we had 3,310 outbreaks identified across the state (since the beginning of the pandemic). This week we have 275 active clusters. That is up from 218 last week.

Our percentage of outbreak related cases is 7.9%, outbreak-related hospitalizations is about 13.4% and outbreak-related deaths is about 33.6%. Just as a reminder to everyone, the way Public Health is able to identify outbreaks is usually when a case investigation is done. Meaning, we are interviewing the case trying to figure out where they might have been exposed and that information is used to identify outbreaks. As the volume of cases has sky rocketed, we are having to prioritize case investigations because we can't get to everyone. All that to say, you've seen these outbreak related percentages coming down but that's probably because we aren't identifying them as well.



We currently have 13 active outbreaks in daycares, 14 in corrections, 13 in group living, 7 in healthcare settings, and 165 active outbreaks in LTCFs (up a lot from 121 last week). We also have 16 in private businesses and 34 in schools (up from 26 last week).

Don't forget, if you are interested in seeing the list of named locations with 5 or more cases within the last 14 days, you can go to the dashboard.



# Kansas COVID-19: Updated Travel Related Quarantine

Туре	Effective Date	Where?
y	Between December 16 and January 20	Andorra
International Travel	Between January 10 and January 20	Isle of Man and San Marino
	On or after January 20	Aruba
Domestic Travel	September 10, 2020	Attendance at any out-of-state or in-state mass gatherings of 500 or more where individuals do not socially distance (6 feet) and wear a mask.
	Between January 10 and January 20	New York and Washington D.C.
Cruises	On or after March 15, 2020	All cruise ships and river cruises

Available at:

To protect and improve the health and environment of all Kansans

For the US list:

1. Remove:

**New York** 

Washington D.C. 2. Keep: None

3. Add: None

For the International list:

1. Remove:

Andorra


Isle of Man

San Marino

2. Keep: None

3. Add:

Aruba



The Isolation and Quarantine FAQ document was updated yesterday.



#### Is a COVID-19 test required at the end of home isolation?

If an individual has access to a test and wants to test, the best approach is to use an antigen test towards the end of the 5-day isolation period. If your test result is positive, you should continue to isolate until day 10. Do not continue to test daily; complete the 10-day isolation. If your test result is negative, you can end isolation, but continue to wear a well-fitting mask around others at home and in public until day 10.

Available at: <a href="https://www.coronavirus.kdheks.gov/DocumentCenter/View/134/Isolation--Quarantine-Guidance-and-FAQs-PDF---11922">https://www.coronavirus.kdheks.gov/DocumentCenter/View/134/Isolation--Quarantine-Guidance-and-FAQs-PDF---11922</a>

To protect and improve the health and environment of all Kansans

As we talked about before, the general population who is eligible to shorten isolation to a 5 day at home followed by 5 days of masking around others. The question that has come up is what if they take a test on day 6 and are positive, what do they do. So, I talk about here that if you are going to take a test at the end of your home isolation it should be an antigen since PCR will probably be positive for a while. If that antigen is positive on day 6, you should complete the rest of your 10 days at home in isolation. Meaning, instead of returning to normal with masking days 6-10, you should stay at home in isolation if that test is positive on day 6. Don't retest over and over, just finish your 10 day isolation.

# Kansas FAQ COVID-19: Updated KDHE Guidance: Isolation and Quarantine

#### What does it mean to be susceptible to COVID-19 disease?

Persons are considered susceptible to COVID-19 disease because they are currently considered NOT immune.

#### The following persons are considered SUSCEPTIBLE:

- Persons who received two doses of a mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) over 5 months ago but have not received a recommended booster shot when eligible.
- Persons who received the single-dose Johnson & Johnson vaccine (completing the primary series) over 2 months ago and have not received a recommended booster shot when eligible.
- Persons who are not vaccinated or have not completed a primary vaccine series AND do not have evidence of recent COVID-19 infection in the last 90 days.

Available at: https://www.coronavirus.kdheks.gov/DocumentCenter/View/134/Isolation--Quarantine-Guidance-and-FAQs-PDF---11922

To protect and improve the health and environment of all Kansans

I also updated what it means to be susceptible or NOT immune to COVID-19.

So, people that received two doses of an mRNA vaccine over 5 months ago and are not boosted if they are eligible (remember, eligibility depends on age).

Also, people that received one dose of Johnson and Johnson over 2 months ago and are not boosted if they are eligible.

And unvaccinated people or people who are not fully vaccinated that do not have evidence of infection in the last 90 days.



How should household contacts calculate their last day of exposure with the new guidance?


A close household contact (someone in their household has COVID-19) should quarantine during the entirety of the case's at home isolation period which is a minimum of 5 days. After that period, the household contact will continue their period of quarantine for an additional 5 days followed by 5 days of masking with a well-fitting mask when indoors and outdoors when around others. If the contact is unable to wear a mask, then the period of quarantine will be an additional 10 days. See the KDHE Isolation and Quarantine Release Graphic for more

information: https://www.coronavirus.kdheks.gov/DocumentCenter/View/1086/Isolation-Quarantine-Release-Graphic-KS-PDF---11922

Available at: <a href="https://www.coronavirus.kdheks.gov/DocumentCenter/View/134/Isolation--Quarantine-Guidance-and-FAQs-PDF---11922">https://www.coronavirus.kdheks.gov/DocumentCenter/View/134/Isolation--Quarantine-Guidance-and-FAQs-PDF---11922</a>


To protect and improve the health and environment of all Kansans

I also tightened up the language around close household contacts. Close HHC should quarantine during the case's isolation period (so a minimum of 5 days) then they continue on with their own 5 day home quarantine plus 5 days of masking around others. If that close HHC can't or won't mask around others, then they should just stay in home quarantine for the 5 days where they could have gone back to normal with a mask.




To help with a visual for when to release cases and close contacts, we have updated the Isolation and Quarantine Release Graphic.


For cases, you isolate at home for a minimum of 5 days after the onset of symptoms (or sample collection if asymptomatic) and released after 5 full days if you are fever free without the use of medication for 24 hours. Then you must wear a mask for an additional 5 days when around others (that's days 6-10).



If that case cannot or will not wear a mask between days 6 and 10, they should just finish out those remaining 5 days in home isolation; meaning it is a minimum of 10 days in home isolation if you won't or can't mask.




For severely ill cases or immunocompromised people, their home isolation period is going to be between 10 and 20 days and they should consult their physician before ending isolation. The consultation with their physician should go through their particular condition and the likelihood that their bodies have mounted a response against infection and they are recovering so it would be safe for them to be around others.




The we get into close contacts by defining who needs to quarantine (i.e. who is NOT immune).

Kansas Release Graphic	d KDHE Guidance: Isolation a	nd Quarantine				
NON-HOUSEHOLD CONTACTS  Able to wear a well-fitting mask  Contacts should quarantine at home for 5 days and get tested on day 5 or later. After that, they should self-monitor for symptoms and continue to wear a mask around others for 5 additional days. If symptoms develop, they must isolate and get tested.						
5 days quarantine at home	Get Tested Mask around others from day 6 to 10					
Day 0 - Day of Exposure	Day 5 or later – Get tested, if possible, and if negative return to normal activities. Wear a mask around others. If positive, isolate for at least 5 days.	Day 10 – Complete self- monitoring for symptoms				
Available at: <a href="mailto:lsolation+QuarantineReleaseGraphic_KS">lsolation+QuarantineReleaseGraphic_KS</a> (kdheks.gov)						
To protect and improve the health and environment of all Kansans						


For non household close contacts, they would quarantine at home for 5 days and get tested on day 5 or later. If they are negative, then they can resume their normal activities but they must wear a mask from days 6 to 10. If they test positive, they would then be a case and would follow the isolation guidance for cases.




If they cannot or will not wear a mask from day 6 to 10, then they should stay home and continue to quarantine at home for those days.



Then we get into the household contacts. If you have a HHC that is able and willing to mask, then they are going to stay at home for the first 5 days while the case is in home isolation (outlined here in the red box). Exposure is considered ongoing at this time. Then the HHC stays home for an additional 5 days in their own home quarantine (yellow box); at the end of those 5 days it is recommended that they get tested. If they don't have symptoms and they are negative, they can return to normal activities but wear a mask around others for an additional 5 days (green box).



If you have a HHC that can't or won't mask, then they are going to stay at home for the first 5 days while the case is in home isolation (outlined here in the red box). Exposure is considered ongoing at this time. Then the HHC stays home for an additional 10 days in their own home quarantine (yellow box).




On the 18th KDHE announced a change to contact outreach and monitoring.

When we say we are sunsetting contact outreach and monitoring, or contact tracing, what we mean is that PH will still try to interview as many cases as possible. Before the change, we would get a list of close contacts and then reach out to those close contacts and let them know about their exposure (that was the outreach part) and then ask if they wanted to be monitored during their incubation period (that was the monitoring part).

We are now entering the third year of public health response and we need to adjust the level of response, partly to help alleviate strain on the public health system but also in response to what we know about this virus. We are currently seeing a virus that is highly infectious but causes milder disease. We have a disease that is most infectious before a person even starts to show symptoms and within the first few days of symptoms, but is also very effective at spreading from completely asymptomatic people. All of that coupled with the sheer volume of cases means that only a very small portion of the total contacts are even being identified. So, it's appropriate to transition our public health resources toward more effective strategies.


Another reason is simply fatigue of the pandemic by the public and less willingness to speak with public health staff about their illness and contacts, resulting in low rates of reaching cases and contacts in a timely fashion.

So we are moving to a strategy of arming people with the knowledge they need if they are a case or if they are a close contact so that they can make the best decisions to protect themselves and others.



To that end, we have launched a couple of different websites, one aimed at close contacts and one aimed at cases.

If you are a close contact, you will first see information to help you figure out if you are susceptible to COVID-19 disease based on assumed immunity from boosters or natural infection within the last 90 days.



# Susceptible close contacts can get information on:

#### How Long do You Need to Quarantine and What Should You do?

**Stay home and quarantine for at least 5 full days** after your last close contact. The day of your last contact is Day 0 and the next day is Day 1. **Wear a well-fitted mask** that covers your mouth and nose if you must be around others in your home.

Even if you don't develop symptoms, **get tested at least 5 days after** you last had close contact with someone with COVID-19.

After at least 5 full days of quarantine at home, you may leave your home. Wear a well-fitted mask that covers your mouth and nose when around others for an additional 5 days. If you cannot mask, continue quarantine at home for an additional 5 days.

Watch for symptoms for 10 days after you last had close contact. If you develop symptoms, isolate immediately and get tested.


Wear a well-fitted mask that covers your mouth and nose for 10 full days after you last had close contact any time you are around others inside your home or in public.

# For 10 full days after you last had close contact:

Avoid any place where you are unable to wear a mask Avoid travel

Avoid being around people who are at high risk of developing severe disease **Use the <u>Quarantine and Isolation Calculator</u>** from the South Dakota Department of

Health to help you determine your recommended quarantine period for non-household close contacts.



# If You Are NOT Considered Susceptible

If you are considered immune, you do not need to quarantine at home unless you develop symptoms. You should:


**Get tested** at least **5 days after** you last had close contact with someone with COVID-19.

**Watch for symptoms** for **10 days** after you last had close contact. If you develop symptoms, isolate immediately and get tested.


Wear a well-fitted mask that covers your mouth and nose any time you are around others inside your home or in public for 10 full days after you last had close contact. For 10 full days after you last had close contact:

Avoid any place where you are unable to wear a mask Avoid travel

Avoid being around people who are at high risk of developing severe disease



If you are case because you tested positive or even if you suspect you have COVID-19 disease, you can find information on this website.



# What Are The Symptoms of COVID-19?

People report a wide range of symptoms, from mild to severe. Symptoms may appear 2-14 days after exposure, and anyone can have symptoms, regardless of vaccination status. Typical symptoms include, but are not limited to:

New loss of taste or smell

Shortness of breath or difficulty breathing

Fever or chills

Cough

**Fatigue** 

Muscle or body aches

Headache

Sore throat

Congestion or runny nose


Nausea or vomiting

Diarrhea

# When to Seek Emergency Medical Attention:

If someone is showing any of these signs, **seek emergency medical care immediately**, or upon experiencing any symptoms that are severe or concerning to you: Trouble breathing

Persistent pain or pressure in the chest New confusion Inability to wake or stay awake Pale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone



# When Are You Contagious & When Can You Get Others Sick?

People with COVID-19 are contagious in the 2 days prior to the start of symptoms and for 10 days after symptoms begin. You are most contagious 2-3 days after symptoms begin, but it is possible to spread the virus for up to 10 days. People who are severely ill with COVID-19 or who are immunocompromised may spread the virus for up to 20 days.

# **COVID-19 Can be Spread by People With no Symptoms**

COVID-19 can be spread by people that don't have symptoms, so people who do not have symptoms are considered contagious in the 2 days prior to when their positive sample was collected. It is possible to spread the virus for up to 10 days.

If You Had Close Contact With Someone When You Might Have Been Contagious If someone was 6 feet or less from a person with a confirmed or suspected COVID-19 infection for a total of 15 minutes over a 24-hour period, they are considered a close contact. For example, someone who had three separate 5-minute exposures to a person with COVID-19 over the course of a single day is considered a close contact. If you had close contact with anyone during the time you might be contagious: Tell each of them that you are sick as soon as you are able.

Recommend that they do the following:

Quarantine at home for 5 full days

Get tested after 5 days

Monitor for symptoms and get tested immediately if symptoms develop

<u>Visit the Close Contacts web page</u>

Symptoms & When to Seek Care Contagiousness & Close	Contacts Isolation	
Why is Isolation Important? Isolation helps stop the spread of COVID-19. People should stay home until it's shome, anyone sick or infected should do the following:	safe to be around others. While at	
<ul> <li>Monitor your <u>symptoms</u>. If symptoms get worse or if you have an <u>emergency warning sign</u> such as trouble breathing or persistent pain or pressure in the chest, seek emergency medical care immediately.</li> </ul>		
Stay in a separate room away from other household members, if possible.		
Use a separate bathroom, if possible.		
Take steps to <u>improve ventilation at home</u> , if possible.		
Avoid contact with other members of the household and pets.		
Don't share personal household items, like cups, towels, and utensils.		
Wear a <u>well-fitting mask</u> if you need to be around others.		

### Why is Isolation Important?

Isolation helps stop the spread of COVID-19. People should stay home until it's safe to be around others. While at home, anyone sick or infected should do the following: Monitor your <u>symptoms</u>. If symptoms get worse or if you have an <u>emergency warning sign</u> such as trouble breathing or persistent pain or pressure in the chest, seek emergency medical care immediately.

Stay in a separate room away from other household members, if possible.

Use a separate bathroom, if possible.

Take steps to <u>improve ventilation at home</u>, if possible.

Avoid contact with other members of the household and pets.

Don't share personal household items, like cups, towels, and utensils.

Wear a <u>well-fitting mask</u> if you need to be around others.

### Length of Isolation

As of January 2022, KDHE has outlined isolation guidelines for two scenarios:

Those who have tested positive and have symptoms

Those who have tested positive and do not have symptoms

### If Positive & Have Symptoms:

**Stay home and isolate for at least 5 days** from when your symptoms began. The day your symptoms start is considered Day 0 and the next day is considered Day 1. **Wear a** 

well-fitted mask that covers your mouth and nose around others in your home. If your symptoms have improved after 5 days AND you have been fever-free for at least 24 hours -- without fever-reducing medications such as acetaminophen or ibuprofen -- you can leave your house. Continue to wear a well-fitted mask that covers your mouth and nose for 5 more days when around others. If you cannot mask, continue to isolate at home for 5 additional days.

### During the entire 10 days you are contagious:

Avoid travel

Avoid being around people at high risk for developing severe disease

If you were severely ill or are immunocompromised, you should isolate at home for at least 10 days and may need to isolate up to 20 days. Consult your doctor before ending isolation.

**Use the** Quarantine and Isolation Calculator from the South Dakota Department of Health to help you determine your recommended isolation period.

### If Positive & No Symptoms:

Stay home and isolate for 5 days from when your positive sample was taken. The day your sample was taken is considered Day 0 and the next day is considered Day 1. Wear a well-fitted mask that covers your mouth and nose around others in your home. If you haven't developed symptoms during your 5 days at home, you can leave your house. If you developed symptoms, follow the guidance for people who tested positive and have symptoms. Begin a new home isolation period based on the day your symptoms start.


**Continue to wear a well-fitted mask** that covers your mouth and nose for 5 more days when around others. If you cannot mask, continue to isolate at home for 5 additional days.

During the 10 days you are contagious:

Avoid travel

Avoid being around people at high risk for developing severe disease **Use the <u>Quarantine and Isolation Calculator</u>** from the South Dakota Department of Health to help you determine your recommended isolation period.

I encourage all of you to please take a look at these resources and, if you find them helpful, to give them to your patients the help educate people and empower them to make good choices.



We also updated the guidance for K-12 schools that are participating in the KDHE testing program.




## **COVID-19: Updated Guidance for K-12 Test to Stay**

Modification if overwhelmed with testing or facing critical shortages in supplies: Test upon notification that someone is a susceptible close contact and test one additional time between Days 5 and 7 after exposure. For household contacts, the second test should be between Days 5 and 7 after last exposure while the case was infectious. More frequent testing of household contacts may be needed because they will be continually exposed (10 days of household members infectious period plus 7 days of close contacts quarantine). If TTS school has PCR use PCR, if not use rapid antigen.

Available at: <a href="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options?bidId="https://www.coronavirus.kdheks.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter/View/2060/K-12-COVID-19-Testing--Vaccine-Options.gov/DocumentCenter

To protect and improve the health and environment of all Kansans

Given the huge surge in cases, we added in a modification to help schools that were facing shortages of supplies or were otherwise unable to keep up with their normal testing plans. Based on a CDC recommendation for a bare minimum testing strategy, we suggested that schools that can't test every other day switch to a strategy of testing upon notification and once again between day 5 and 7 after last exposure.



A memo was also jointly issued by KDHE and the Kansas State Board of Education on the 17<sup>th</sup>. This memo essentially said that, if schools needed to, they could pause contact tracing for 30 days. The memo encourages schools, especially Test to Stay schools, that can continue to contact trace that they do so. Meaning, they still find those susceptible close contacts at school and test them either every other day or switch to the strategy of just testing them upon notification and again between day 5 and 7.



**Expectation for Test to Stay School Districts:** 


- During a temporary suspension of close contact identification in K-12 settings, consider:
  - Switch to diagnostic testing to support students/teachers/staff who become symptomatic during the school day and/or for students/teachers/staff that call and notify the school that they are symptomatic.
  - Focus on antigen testing for people coming back from 5 days of home isolation after testing positive. This can be a
    one-time test on the morning of return to school with the option to test again the following morning.
  - Focus on antigen or PCR testing for people coming back from 5 days of home quarantine. This can be a one-time
    test on the morning of return to school with the option to test more often.

Again, we thank you for everything you are doing to provide for your community during these unprecedented times. Please continue to communicate with us as we all try to navigate the current situation.

To protect and improve the health and environment of all Kansans

However, for our TTS schools that can't do that right now, we suggested a 30 day strategy of just diagnostic testing, just testing people coming back from home isolation and just testing people coming back from home quarantine.

I know there have been a lot of questions from school districts on what all of these changes really mean so we are working with KSDE to maybe have an question and answer session with principals and school nurses.



To examine the impact of primary COVID-19 vaccination and previous SARS-CoV-2 infection

Four cohorts of adults aged ≥18 years were considered: persons who were 1) unvaccinated with no previous laboratory-confirmed COVID-19 diagnosis, 2) vaccinated (14 days after completion of a primary COVID-19 vaccination series) with no previous COVID-19 diagnosis, 3) unvaccinated with a previous COVID-19 diagnosis, and 4) vaccinated with a previous COVID-19 diagnosis.

During the study period, COVID-19 incidence in both states was highest among unvaccinated persons without a previous COVID-19 diagnosis compared with that among the other three groups.

During the week beginning May 30, 2021, compared with COVID-19 case rates among unvaccinated persons without a previous COVID-19 diagnosis, COVID-19 case rates were 18-20 fold lower among vaccinated persons without a previous diagnosis; 7-10 fold lower among unvaccinated persons with a previous COVID-19 diagnosis; and 9 to 10 fold lower among vaccinated persons with a previous COVID-19 diagnosis.

These relationships changed after the SARS-CoV-2 Delta variant became predominant (i.e., accounted for >50% of sequenced isolates) in late June and July.

By the week beginning October 3, compared with COVID-19 cases rates among unvaccinated persons without a previous COVID-19 diagnosis, case rates among vaccinated persons without a previous COVID-19 diagnosis were 5 to 6 fold lower; 15-29 fold lower among unvaccinated persons with a previous diagnosis, and 20 to 32 fold lower among vaccinated persons with a previous diagnosis of COVID-19.

infection-derived protection was higher after the Delta variant became predominant




## **COVID-19: New Omicron Literature**

- •Children are less likely to have severe symptoms from Omicron vs. Delta.
- •Omicron was found to be 25% less virulent than Delta in South Africa.
- •In the UK, fewer patients report loss of taste/smell, shortness of breath, fatigue, and muscle aches, but more patients reported sore throats if they contracted SARS-CoV-2 when Omicron was predominant vs. when other variants were predominant.
- •The combination of original vaccine and booster vaccine did not impact the amount of neutralizing antibody against Delta or Omicron with the exception that patients that received Janssen as the original and booster vaccine had lower neutralizing antibodies than the other groups.
- •Infection with Delta, but not Omicron, induces broad immunity in mice.
- •Human sera from Omicron and Delta breakthrough cases reveals effective cross-variant neutralization induced by both viruses in vaccinated individuals (sera from unvaccinated, but previously infected, individuals did not have as broad of neutralizing capacity).
- •Immunocompromised patients that contracted SARS-CoV-2 for long periods of time (> 8 months) promoted the emergence of novel SARS-CoV-2 mutations over time.

To protect and improve the health and environment of all Kansans

Bullet # 4: Summary: This study investigated the neutralizing antibody titers of individuals who received the same booster vaccine as their original vaccine versus a different booster vaccine from their original vaccine. Overall, the authors found that the combination of original vaccine and booster vaccine did not impact the amount of neutralizing antibody against Delta or Omicron with the exception that patients that received Janssen as the original and booster vaccine had lower neutralizing antibodies than the other groups.



COVID infection severity in children under 5 years old before and after Omicron emergence in the US

Lindsey Wang, Nathan A. Berger, David C. Kaelber, <sup>1</sup> Pamela B. Davis, <sup>1</sup> Nora D. Volkow, <sup>1</sup> Rong Xu

doi: https://doi.org/10.1101/2022.01.12.22269179

#### Major findings:

• In the 3 days after infection, children under 5 that contracted SARS-CoV-2 for the first time during a time when Omicron was the dominant variant (12/26/2021-1/6/2022) were less likely to require an ED visit (RR(risk ratio): 0.71), hospitalization (RR: 0.33), ICU admission (RR:0.32), or mechanical ventilation (RR: 0.29) versus children who contracted SARS-CoV-2 the first time during a time when Delta was dominant.

Limitations: Omicron and Delta groups were identified based on the prevalence of the variant in the population and not WGS results.

URL: https://www.medrxiv.org/content/10.1101/2022.01.12.22269179v1

Summary: The study used electronic health records for 79,592 children under 5 who contracted SARS-CoV-2 infection for the first time, including 7,201 infected between 12/26/2021-1/6/2022 when the Omicron variant was predominant. The children were matched by propensity-score matching for demographics, socio-economic determinants of health, comorbidities and medications and compared between children that were infected with SARS-CoV-2 for the first time when Omicron was the predominant variant and children that were infected with SARS-CoV-2 for the first time when Delta was the predominant variant. Children who were infected during the Omicron predominant period had lower rates of ED visits, hospitalizations, ICU admissions, and mechanical ventilations versus children who were infected during the Delta predominant period.

Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa

Mary-Ann Davies, Reshma Kassanjee, Petro Rosseau, Erna Morden, Leigh Johnson, Wesley Solomon, Nei-Yuan Hsiao, Hannah Hussey, Graeme Meintjes, Masudah Paleker, Theuns Jacobs, Peter Raubenheimer, Alexa Heekes, Pierre Dane, Jamy-Lee Bam, Mariette Smith, Wolfgang Preiser, David Pienaar, Marc Mendelson, Jonathan Naude, Neshaad Schrueder, Ayanda Mnguni, Sue Le Roux, Katie Murie, Hans Prozesky, Hassan Mahomed, Liezel Rossouw, Sean Wasserman, Deborah Maughan, Linda Boloko, Barry Smith, Jantije Taljaard, Greg Symons, Ntobeko Ntusi, Arifa Parker, Nicole Wolter, Waasila Jassat, Cheryl Cohen, Richard Lessells, Robert J Wilkinson, Juanita Arendse, Saadiq Kariem, Melvin Moodley, Krish Vallabhjee, Millani Wolmarans, Keith Cloete, Andrew Boulle

doi: https://doi.org/10.1101/2022.01.12.22269148

#### Major findings:


In the 14 days after infection, in a population aged ≥20 years that had been infected with SARS-CoV-2 during a time
when Delta was predominant vs. a time when Omicron was predominant, the authors found that much of the
reduction in severity seen in patients that likely had Omicron vs. Delta was the result of prior infection and
vaccination, but that Omicron may be 25% less virulent than Delta.

Limitations: Omicron and Delta groups were identified based on the prevalence of the variant in the population and not WGS results.

URL: https://www.medrxiv.org/content/10.1101/2022.01.12.22269148v1

Summary: The study used participants who contracted SARS-CoV-2 during a time when Omicron was predominant (5,144 patients) and a time when Delta was predominant (11,609 patients). Two analyses were performed, one which had patients were grouped by age, sex, comorbidities, and geography and the second analyses grouped by all the variables in the first analyses, but also included vaccination status and prior infection. After adjusting for vaccination status and prior infection, the authors found that there was a 25% reduction in severe hospitalization or death in the group that was infected when Omicron was the predominant variant vs. Delta.





Summary: This study used the UK Covid-19 Infection Survey, a nationally representative longitudinal household survey, to investigate the predominant symptoms of patients infected when Omicron was predominant (December 2021) vs. other variants (October 2020 to November 2021). Between October-2020 and December-2021, 53,617 PCR-positive episodes occurred in 52,869 participants (median 40 years, IQR 17-56), with 28,882 (54%) reporting symptoms. Patients did not have some of the characteristic COVID-19 symptoms such as loss of taste/smell during a time when Omicron was predominant. The authors suggest that this change in symptoms in people who likely have Omicron may result in people infected with Omicron assuming they do not have COVID-19 because it does not match some of the characteristic COVID-19 symptoms.

Vaccination/Prior Infection

## SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting

Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul Paul Chourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck Jr., Martin Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Janet I. Archer, Sonja Crandon, Jillian A. Zemanek, Elizabeth R. Brown, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Seema U. Nayak, Paul C. Roberts, John H. Beigel, David Montefiori, the DMID 21-0012 Study Group

doi: https://doi.org/10.1101/2022.01.13.22268861

#### Major findings:

- Patients that received the same booster vaccine as their original vaccine did not have different neutralizing antibody
  titers versus patients that received a different booster vaccine from their original vaccination with the exception of
  patients that received Janssen as the original and booster vaccine.
  - Patients that received Janssen as the original and booster vaccine had lower neutralizing antibody titers vs.
    patients that received Janssen as the original and Pfizer as the booster (Moderna was not tested)

Limitations: None, this was a good and simple paper.

URL: https://www.medrxiv.org/content/10.1101/2022.01.13.22268861v1

Summary: This study investigated the neutralizing antibody titers of individuals who received the same booster vaccine as their original vaccine versus a different booster vaccine from their original vaccine. Overall, the authors found that the combination of original vaccine and booster vaccine did not impact the amount of neutralizing antibody against Delta or Omicron with the exception that patients that received Janssen as the original and booster vaccine had lower neutralizing antibodies than the other groups.

#### Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination

Rahul K. Suryawanshi, O Irene P Chen, Tongcui Ma, O Abdullah M. Syed, Camille R Simoneau, Alison Ciling, Mr M. Khalid, O Bharath Sreekumar, Pei-Yi Chen, Ashley F. George, G. Renuka Kumar, Mauricio Montano, Miguel A Garcia-Knight, Noah Brazer, Prachi Saldhi, Alicia Sotomayor-Gonzalez, Venice Servellita, Amelia Gliwa, Jenny Nguyen, Ines Silva, Bilal Milbes, Noah Kojima, Victoria Hess, Maria Shacreaw, Lauren Lopez, Matthew Brobeck, Fred Turner, O Frank W Soveg, Xiaohai Fang, Maz Maishan, Michael Matthay, Mary Kate Morris, Debra Wadford, Carl Hanson, Warner C. Greene, Raul Andino, Lee Spraggon, Nadia R. Roan, Charles Y. Chiu, O Jennifer Doudna, O Melanie Ott


#### Major findings:

- · Infection with Delta, but not Omicron, induces broad immunity in mice.
  - Sera from Omicron-infected mice only neutralize Omicron, sera from Delta-infected mice are broadly effective against Delta and other VOCs, including Omicron
- Human sera from Omicron and Delta breakthrough cases reveals effective cross-variant neutralization induced by both viruses in vaccinated individuals.
  - Sera from individuals who were not vaccinated prior to infection with Delta neutralized WA1 and Delta variants, but not Omicron.

#### Limitations:

URL: <a href="https://www.medrxiv.org/content/10.1101/2022.01.13.22269243v1">https://www.medrxiv.org/content/10.1101/2022.01.13.22269243v1</a>

Summary: The authors set out to investigate if mass infection with Omicron would result in "herd immunity" from SARS-CoV-2 and if prior infection with Delta would result in some level of immunity against Omicron. Mice were infected with Delta or Omicron and given time to have an immunological response after which their sera was collected. The effectiveness of the sera to neutralize WA1 (ancestral), Alpha, Beta, Delta, and Omicron variants. Sera isolated from mice infected with Delta were able to broadly neutralize all variants except Beta while sera from mice infected with Omicron only nuetralized the Omicron variant. Sera isolated from vaccinated humans who had breakthrough infections with Delta or Omicron were able to neutralize all variants while sera from unvaccinated humans was not able to neutralize all variants. Notably, sera from vaccinated individuals with confirmed Omicron breakthrough infection showed the highest level of protection (>80%) against all strains, including Omicron. These findings suggest that Omicron infection can effectively boost existing immunity conferred by the vaccination against other variants, eliciting "hybrid immunity" that is effective against not only itself but also other variants.



# Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease

Anna C. Riddell, Beatrix Kele, Kathryn Harris, Jon Bible, Maurice Murphy, Subathira Dakshina, Nathaniel Storey, Dola Owoyemi, Corinna Pade, Joseph M. Gibbons, David Harrington, Eliza Alexander, Áine McKnight, Teresa Cutino-Moguel

doi: https://doi.org/10.1101/2022.01.14.21267836

#### Major findings:

• Three immunocompromised patients with persistent (> 8 months) SARS-CoV-2 infections were shown to promote the emergence of novel SARS-CoV-2 mutations over time.


Limitations:

URL: https://www.medrxiv.org/content/10.1101/2022.01.14.21267836v1

Summary: This study used regular WGS to assess the genome of SARS-CoV-2 in patients who were immunocompromised and had persistent SARS-CoV-2 infections. In all three patients there was a generation of novel mutations over time, some of which persisted. This persistence is presumably due to selection pressure, and therefore is evidence of active viral replication. These findings provide further evidence that in the setting of immunosuppression, individuals can

have chronic SARS-CoV-2 infection providing an opportunity for the generation of novel variants. All three patients had CD4 lymphopenia, supporting a critical role for CD4 T-cells in the clearance of SARS-CoV-2 infection.







## **Order Vaccine As Needed**

## **Avoid missed opportunities!**

# Minimum order is 1 vial of any vaccine through direct shipment form KDHE

How to receive vaccine: To place an order for vaccine for delivery next week, please complete the following order form as soon as possible and no later than Wednesday 5pm CT.

Please keep Vaccine Finder current.

This impacts vaccine.gov and visibility of the vaccine you have available to administer in addition to ordering caps for the state.



# Kansas Supreme Court Rulings

On Thursday January 13th 2022, the Supreme Court issued split decisions on the Biden Administration's federal vaccine mandates.

- The Court struck down the Occupational Safety and Health Administration (OSHA) vaccine-or-test requirement for employers.
- The Court upheld the Centers for Medicare and Medicaid Services (CMS) vaccine mandate for health care workers in facilities receiving Medicare or Medicaid funds.





### CDC Data Discrepancies (USA Today article)

**Uneven Reporting Raises Doubts About CDC Vaccination Numbers** - Read <u>here</u>. Article touching on some of the issues between data reporting for doses administered by state vs. federal entities brought up by Association of Immunization Managers members.

- The agency has acted to address inconsistencies in its data tracker. But experts say the solution does little to correct reporting that has miscounted the vaccination status of millions.
- Kaiser Health News this month reported that the tracker showed 99.9% of people ages 65 and older had at least their first shot a number that experts said couldn't be correct.
- The CDC responded by quietly instituting a cap across the demographic groups they measure
  that, on paper, prevents any group from exceeding a vaccination rate of 95%. Its tracker now
  shows that 95% of those 65 and older are at least partially vaccinated instead of 99.9%.
- A new footnote explains that the cap "helps address potential overestimates of vaccination coverage due to first, second, and booster doses that were not linked." It also notes that inaccuracies could arise from part-time residents getting the shots and potential data reporting errors
- Experts say CDC's strategy does not solve underlying data issues that could spawn massive
  miscounts and that it's important for vaccination coverage data to be accurate so that public health
  policies can be targeted to where they are most needed.



## Omicron Threat to Organ Transplant Patients (USA Today article)

Why Omicron Is a Dangerous Threat for Transplant Patients- Read <a href="here">here</a>. For organ transplant patients and other immunocompromised individuals, the omicron variant ushered in a particularly fraught phase of the pandemic.

- The emergence of the omicron variant of COVID-19, which is more contagious and multiplies 70 times faster than its delta counterpart, has brought with it a potentially life-threatening period this winter for individuals who are elderly, immunocompromised or unvaccinated. One group that is particularly vulnerable but often overlooked is those who have received organ transplants.
- Transplant patients may not respond the same way to vaccines. A recent study reported that
  vaccinated transplant patients faced a more than 80-fold higher risk of a COVID-19 breakthrough
  infection than the general population of fully vaccinated adults, as well as a 485-fold risk of
  breakthrough infection with associated hospitalization and death. In a separate study, organ
  transplant patients who received a third dose of Moderna's mRNA vaccine had an improved
  antibody response against the delta variant, but it's too early to know if this response will hold up
  against omicron.
- Prioritizing a third dose of vaccine in transplant patients, as well as boosters for their family members and all close contacts (what we call "ring vaccination" or "cocooning"), can protect against severe disease and death.



# Kansas Additional Dose Clarification

Moderately and Severly Immunocompromised							
Vaccine Type	Age	Primary Series	Primary Interval	Booster After			
Pfizer-BioNTech (orange cap)	5 - 11	3 doses	21 days for first two doses then 28 for third	5 Months			
Pfizer-BioNTech (gray cap)	12+	3 doses	21 days for first two doses then 28 for third	5 Months			
Moderna	18+	3 doses	28 days	5 Months			

 $\underline{https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html\#additional-primary-dose}$ 



# Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccine

### Session topics include:

- •Introduction of the DO NOT DILUTE / Gray Cap formulation for individuals 12 years of age and older.
- •Use of each vaccine presentation, including storage, handling, preparation, and administration for:
  - Ages 5 through 11 Years: DILUTE BEFORE USE/Orange Cap
  - Ages 12 Years and Older:
    - DO NOT DILUTE/Gray Cap
    - DILUTE BEFORE USE/Purple Cap
- •Recent medical updates regarding the vaccine
- •An overview of healthcare provider resources
- Question and answer session


These sessions will be **updated** to reflect new information and changes that evolve. Recent updates will be identified at the start of each session.





# Kansas Pfizer Training and Updates

Date and Time with link	Password
Attendee link – Thurs January 6 - 12pm ET	QmagnVap422
Attendee link – Tues January 11 - 3pm ET	cKXFZSiW634
Attendee link – Wed January 12 - 12pm ET	v9MUab6Yrd6
Attendee link – Thurs January 13 - 12pm ET	BXke23nMVD3
Attendee link – Tues January 18 - 3pm ET	FJjvmeG327W
Attendee link – Wed January 19 - 12pm ET	kMapPATn986
Attendee link – Thurs January 20 - 12pm ET	grB3WCzru23
Attendee link – Tues January 25 - 3pm ET	AQqwYfKE522
Attendee link – Wed January 26 - 12pm ET	2pSQT324TdC
Attendee link – Thurs January 27 - 12pm ET	yVDHYiaF828


 $\underline{https://www.pfizermedicalinformation.com/en-us/medical-updates}$ 








https://covid.cdc.gov/covid-data-tracker/?CDC\_AA\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fgenomic-surveillance-dashboard.html#variant-proportions



https://covid.cdc.gov/covid-data-tracker/?CDC\_AA\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fgenomic-surveillance-dashboard.html#variant-proportions



https://covid.cdc.gov/covid-data-tracker/?CDC\_AA\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fgenomic-surveillance-dashboard.html#variant-proportions

Regionally, Interesting to note that we were leaders in Delta becoming dominant but seem to be on the slower end of Omicron becoming dominant strain.



# Kansas COVID-19: Laboratory Update

# **Federal Update**

- FDA has tested over 10 different Antigen tests (most or all OTC) and all detect Omicron.
- · Federal System for citizens to order coming online
  - Covidtests.gov
- Up to 4 per home, 7-12 days
- Website directs to other testing options for immediate needs.




# Kansas COVID-19: Laboratory Update

# **Helpful Contacts**

- General Laboratory Information and LABXCHANGE
  - KDHE.KHELINFO@ks.gov
- **CLIA Certification Questions:** 
  - KDHE.CLIA2@ks.gov
- **School Testing Program Contact** 
  - Sarah Allin, K-12 Funding Project Manager
  - Sarah.allin@ks.gov
- **Courier Service** 
  - Chad Yamashita (Chad. Yamashita@ks.gov)







#### **Allocation of Monoclonal Antibodies**

- A number of alternative therapeutics are available, including oral and IV antivirals, that are effective against omicron
  - NIH recommended IV Remdesivir for therapy consideration in outpatients
- If delta represents a significant proportion of infections and other options are not available or are contraindicated, eligible patient can be offered BAM/ETE or REGEN-COV, with the understanding that these treatments would be ineffective if patients are infected with omicron
  - SARS-CoV-2 Variant by County <a href="https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas">https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas</a>
- The therapeutics supply chain is seeing some significant impacts from omicron both in the manufacturing/warehouse space as well as the distribution side.




#### Kansas CMS Code for Outpatient Veklury (remdesivir) use

- Following recent statement from NIH COVID-19 Treatment Guidelines Panel regarding therapies for COVID-19 omicron variant, CMS created HCPCS code J0248 for the Veklury (remdesivir) antiviral medication when administered in outpatient setting – currently off label
- Code available for use by all payers
- Effective dates of service on or after December 23, 2021
  - Long descriptor: Injection, remdesivir, 1 mg
  - · Short descriptor: Inj, remdesivir, 1 mg
- · Medicare Administrative Contractors determine Medicare coverage when no national coverage determination, including when providers use FDA-approved drugs for indications other than what is on approved label
- MACs will determine Medicare coverage for HCPCS code J0248 for Veklury (remdesivir) administered in outpatient setting
- See CMS COVID-19 Provider Toolkit for additional information



#### Kansas HHS Protect/TeleTracking Reporting

- Therapeutic Course Inventory and Usage Report Once Weekly for Wednesday's Date
  - Therapeutic A Courses on Hand Casirivimab/Imdevimab
  - Therapeutic A Courses Administered in Last Week Casirivimab/Imdevimab
  - Therapeutic C Courses on Hand Bamlanivimab/ Etesevimab
  - Therapeutic C Courses Administered in Last Week Bamlanivimab/ Etesevimab
  - Therapeutic D Courses on Hand Sotrovimab REQUIRED JANUARY 19, 2022
  - Therapeutic D Courses Administered in Last Week Sotrovimab REQUIRED JANUARY 19, 2022
- Therapeutic Course Inventory and Usage Report Daily
  - Evusheld, Molnupiravir, Paxlovid
- https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/COVID19-therapeutics-teletracking.aspx





# Kansas Therapies Questions

• If you have any questions related to monoclonal antibody distribution in Kansas, please contact Michael McNulty (mike.mcnulty@ks.gov)





### **Changes to Contact Tracing**



Press Release January 18

As of Feb. 1, 2022, COVID-19 contact outreach and monitoring, otherwise known as contact tracing, operations will be discontinued at KDHE.

County Local Health Departments have already begun to wind down contact tracing and K-12 schools who were participating in contact tracing as part of the Test to Stay program may temporarily suspend contact tracing as well.

Available at: https://www.kdhe.ks.gov/CivicAlerts.aspx?AID=100



## **Website Updates**



If you have or suspect COVID-19

If you are a close contact

Spanish Flu Toolkit



# Free COVID-19 Tests

# Get free at-home COVID-19 tests

Every home in the U.S. is eligible to order 4 free at-home COVID-19 tests. The tests are completely free. Orders will usually shin in 7-12 days

Order your tests now so you have them when you need them.

Order Free At-Home Tests


If you need a COVID-19 test now, please see <u>other testing</u> <u>resources</u> for free testing locations in your area.

Available at: <a href="https://www.covidtests.gov/">https://www.covidtests.gov/</a>





## Free COVID-19 Tests



Available at: https://www.covidtests.gov/faq/


ABOUT THE AT-HOME COVID-19 TESTS

#### The tests available for order:


- Are rapid antigen at-home tests, not PCR
- Can be taken anywhere
- Give results within 30 minutes (no lab drop-off required)
- Work whether or not you have COVID-19 symptoms
- Work whether or not you are up to date on your COVID-19 vaccines
- Are also referred to as self-tests or over-the-counter (OTC) tests



They have added some good questions to combat misinformation over the last couple weeks.



Along with getting vaccinated and boosted, wearing a well-fitting mask over your mouth and nose in indoor public settings or crowds is crucial to protect yourself and others from COVID-19. Experts recommend you upgrade your mask to a high filtration respirator if you want optimal protection. Use this resource to promote the highest level of mask protection in your community. The resource is also available in Spanish.



Here are some great videos that you can use on social media. Doctors, nurses and community health workers answer some of the common COVID questions we all are getting. These videos are available in English and Spanish.

